US4925919A
(en)
*
|
1984-04-25 |
1990-05-15 |
Roland Mertelsmann |
Purified interleukin 2
|
US4992271A
(en)
*
|
1982-09-23 |
1991-02-12 |
Cetus Corporation |
Formulation for lipophilic IL-2 proteins
|
US4853332A
(en)
*
|
1982-10-19 |
1989-08-01 |
Cetus Corporation |
Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
|
US4569790A
(en)
*
|
1984-03-28 |
1986-02-11 |
Cetus Corporation |
Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
|
DE3583880D1
(de)
*
|
1984-04-09 |
1991-10-02 |
Takeda Chemical Industries Ltd |
Stabile interleukin-2-zusammensetzung.
|
US4908434A
(en)
*
|
1984-04-25 |
1990-03-13 |
Sloan-Kettering Institute For Cancer Research |
Process for preparing purified interleukin-2
|
US4908433A
(en)
*
|
1984-04-25 |
1990-03-13 |
Sloan-Kettering Institute For Cancer Research |
Uses of interleukin-2
|
US4572798A
(en)
*
|
1984-12-06 |
1986-02-25 |
Cetus Corporation |
Method for promoting disulfide bond formation in recombinant proteins
|
GB8508340D0
(en)
*
|
1985-03-29 |
1985-05-09 |
Creighton T E |
Production of protein
|
US5425940A
(en)
*
|
1986-04-09 |
1995-06-20 |
Cetus Oncology Corporation |
Combination therapy using interleukin-2 and tumor necrosis factor
|
DE3621828A1
(de)
*
|
1986-06-28 |
1988-01-14 |
Biotest Pharma Gmbh |
Stabilisierung eines fuer therapeutische zwecke, insbesondere beim menschen, bestimmten interleukin-2-praeparates sowie dieses praeparat enthaltende stabilisierte waessrige loesung oder feststoff
|
US4683293A
(en)
*
|
1986-10-20 |
1987-07-28 |
Phillips Petroleum Company |
Purification of pichia produced lipophilic proteins
|
US4929700A
(en)
*
|
1987-04-16 |
1990-05-29 |
Cetus Corporation |
Production of purified, biologically active, bacterially produced recombinant human CSF-1
|
CA1339757C
(fr)
|
1987-04-16 |
1998-03-17 |
Robert F. Halenbeck |
Methode de production bacteriologique de csf-1 humain recombinant biologiquement actif pur
|
WO1988008849A1
(fr)
*
|
1987-05-11 |
1988-11-17 |
Cetus Corporation |
Procede de recuperation, a partir de microorganismes, d'interleukine-2 recombinante, purifiee, oxydee et renaturee
|
US4961969A
(en)
*
|
1987-05-11 |
1990-10-09 |
Cetus Corporation |
Process for recovering microbially produced interferon-β
|
US4931543A
(en)
*
|
1987-05-11 |
1990-06-05 |
Cetus Corporation |
Process for recovering microbially produced interleukin-2
|
US4801691A
(en)
*
|
1987-05-15 |
1989-01-31 |
International Minerals & Chemical Corp. |
Method for removing sodium dodecyl sulfate from sodium dodecyl sulfate solubilized protein solutions
|
JP2669859B2
(ja)
*
|
1987-08-04 |
1997-10-29 |
協和醗酵工業株式会社 |
タンパク質の再活性化法
|
US5759815A
(en)
*
|
1988-02-11 |
1998-06-02 |
Creative Biomolecules, Inc. |
Production of platelet derived growth factor (PDGF) an muteins thereof
|
CA1340586C
(fr)
*
|
1988-09-23 |
1999-06-08 |
Cetus Corporation |
Methode pour recuperer l'interferon beta produit par voie microbienne
|
JP2517100B2
(ja)
*
|
1989-03-08 |
1996-07-24 |
協和醗酵工業株式会社 |
ヒト顆粒球コロニ―刺激因子活性を有する蛋白質の精製法
|
US5204256A
(en)
*
|
1989-09-06 |
1993-04-20 |
Behringwerke Aktiengesellschaft |
Process for the purification of plasminogen activator inhibitor 2 (pai-2)
|
AU6870791A
(en)
*
|
1989-10-18 |
1991-05-16 |
Creative Biomolecules, Inc. |
Biosynthetic constructs of tgf-beta
|
GB8927546D0
(en)
*
|
1989-12-06 |
1990-02-07 |
Ciba Geigy |
Process for the production of biologically active tgf-beta
|
US5830452A
(en)
*
|
1990-11-20 |
1998-11-03 |
Chiron Corporation |
Method for enhancing the anti-tumor therapeutic index of interleukin-2
|
DK0511964T3
(da)
*
|
1990-11-23 |
1998-06-02 |
Roussel Uclaf |
Fremgangsmåde til fremstilling af et cytokin protein med mindst en intramolekylær disulfidbro ved reduktion af det tilsvarende reducerede rekombinante protein ved en pH-værdi lavere end 5,0
|
IT1245063B
(it)
*
|
1991-04-12 |
1994-09-13 |
Ferruzzi Ricerca & Tec |
Procedimento per l'ossidazione di carboidrati
|
US5466781A
(en)
*
|
1991-05-24 |
1995-11-14 |
Chiron Therapeutics |
Process for purifying bacterially produced M-CSF
|
US5288931A
(en)
*
|
1991-12-06 |
1994-02-22 |
Genentech, Inc. |
Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
|
FR2684878B1
(fr)
*
|
1991-12-12 |
1994-02-11 |
Roussel Uclaf |
Composition pharmaceutique stabilisee d'il2 humaine recombinante non glycosylee sous forme reduite et son procede de preparation.
|
US6063764A
(en)
*
|
1992-06-01 |
2000-05-16 |
Washington University & Chiron Corp. |
Method for using lipoprotein associated coagulation inhibitor to treat sepsis
|
US20030171292A1
(en)
*
|
1992-06-01 |
2003-09-11 |
Creasey Abla A. |
Method for using lipoprotein associated coagulation inhibitor to treat sepsis
|
CA2147466A1
(fr)
*
|
1992-10-20 |
1994-04-28 |
Just P. J. Brakenhoff |
Antagonistes du recepteur de l'interleukine-6
|
NZ271088A
(en)
*
|
1993-08-04 |
1996-10-28 |
Ciba Geigy Ag |
Desulphatohirudin muteins, their production, conjugates thereof and pharmaceutical compositions
|
US5663304A
(en)
*
|
1993-08-20 |
1997-09-02 |
Genentech, Inc. |
Refolding of misfolded insulin-like growth factor-I
|
US5545723A
(en)
*
|
1994-03-15 |
1996-08-13 |
Biogen Inc. |
Muteins of IFN-β
|
TW517059B
(en)
|
1994-07-25 |
2003-01-11 |
Ciba Geigy Ag |
New process for the production of biologically active protein
|
DE19547933A1
(de)
*
|
1995-12-22 |
1997-06-26 |
Boehringer Mannheim Gmbh |
Multimere Formen von IL-16, Verfahren zu ihrer Herstellung und Verwendung
|
AU735459B2
(en)
|
1997-01-30 |
2001-07-12 |
University Of Virginia Patent Foundation |
Cysteine-depleted peptides recognized by A3-restricted cytotoxic lymphocytes, and uses therefor
|
US20080076706A1
(en)
|
1997-07-14 |
2008-03-27 |
Bolder Biotechnology, Inc. |
Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
|
ES2297889T3
(es)
|
1997-07-14 |
2008-05-01 |
Bolder Biotechnology, Inc. |
Derivados de hormona de crecimiento y proteinas relacionadas.
|
US6753165B1
(en)
|
1999-01-14 |
2004-06-22 |
Bolder Biotechnology, Inc. |
Methods for making proteins containing free cysteine residues
|
US7270809B2
(en)
|
1997-07-14 |
2007-09-18 |
Bolder Biotechnology, Inc. |
Cysteine variants of alpha interferon-2
|
GB9806632D0
(en)
*
|
1998-03-28 |
1998-05-27 |
Stevenson Robert |
Peptide factor
|
CA2359345A1
(fr)
*
|
1999-01-14 |
2000-07-20 |
Bolder Biotechnology, Inc. |
Techniques permettant de produire des proteines contenant des residus cysteine libres
|
US8288126B2
(en)
|
1999-01-14 |
2012-10-16 |
Bolder Biotechnology, Inc. |
Methods for making proteins containing free cysteine residues
|
US6808902B1
(en)
*
|
1999-11-12 |
2004-10-26 |
Amgen Inc. |
Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
|
EP1935431A3
(fr)
|
2000-05-15 |
2008-08-13 |
Health Research, Inc. |
Traitements anti-cancéreux utilisant une combinaison d'anticorps contre le HER2 et l'interleukine-2
|
US6887462B2
(en)
|
2001-04-09 |
2005-05-03 |
Chiron Corporation |
HSA-free formulations of interferon-beta
|
BR0213292A
(pt)
*
|
2001-10-15 |
2006-05-23 |
Chiron Corp |
tratamento de pneumonia severa por administração de inibidor da via de fator tecidual (tfpi)
|
RU2006104023A
(ru)
*
|
2003-07-11 |
2006-07-27 |
Шеринг Акциенгезельшафт (De) |
УЛУЧШЕННЫЕ РЕКОМБИНАНТНЫЕ ПОЛИПЕПТИДЫ ЧЕЛОВЕЧЕСКОГО ИНТЕРФЕРОНА -БЕТА-1b
|
EP2248830A1
(fr)
|
2003-11-04 |
2010-11-10 |
Novartis Vaccines and Diagnostics, Inc. |
Utilisation d'anticorps antagonistes anti-CD40 pour le traitement de maladies autoimmunes et inflammatoires et le rejet d'organes transplantés
|
CA2560103A1
(fr)
*
|
2004-03-17 |
2005-11-24 |
Chiron Corporation |
Traitement de la pneumonie extra-hospitaliere grave par administration de l'inhibiteur de parcours de facteur tissu (tfpi)
|
DE17196350T1
(de)
|
2007-07-09 |
2018-12-27 |
Genentech, Inc. |
Verhindern der disulfid-bindungsreduktion während der rekombinanten herstellung von polypeptiden
|
EP2207890A4
(fr)
*
|
2007-10-05 |
2010-12-15 |
Barofold Inc |
Traitement sous haute pression d'interférons agrégés
|
WO2010125187A2
(fr)
|
2009-04-30 |
2010-11-04 |
Ablynx Nv |
Procédé de production d'anticorps à domaines
|
KR101741859B1
(ko)
*
|
2009-06-22 |
2017-06-15 |
암젠 인크 |
화학적으로 조절된 산화환원 상태를 사용한 단백질의 재폴딩
|
WO2010151688A2
(fr)
|
2009-06-25 |
2010-12-29 |
Amgen Inc. |
Procédés de purification par capture de protéines exprimées dans un système non mammifère
|
US9428567B2
(en)
|
2010-12-22 |
2016-08-30 |
The Board Of Trustees Of The Leland Stanford Junior University |
Antagonists of interleukin-2 receptor
|
GB201101794D0
(en)
*
|
2011-02-02 |
2011-03-16 |
Fermentas Uab |
Protein production
|
WO2015042707A1
(fr)
|
2013-09-24 |
2015-04-02 |
Medicenna Therapeutics Pte Ltd |
Protéines hybrides de l'interleukine-2 et leurs utilisations
|
EP3134102B1
(fr)
|
2014-04-24 |
2019-07-03 |
The Board of Trustees of The Leland Stanford Junior University |
Superagonistes, agonistes et antagonistes partiels de l'interleukine-2
|
EP3204119B1
(fr)
|
2014-10-09 |
2021-06-09 |
Dana-Farber Cancer Institute, Inc. |
Schéma posologique d'il-2 variables multiples pour le traitement de troubles immunitaires
|
AU2018234810B2
(en)
|
2017-03-15 |
2023-05-11 |
Pandion Operations, Inc. |
Targeted immunotolerance
|
WO2018217989A1
(fr)
|
2017-05-24 |
2018-11-29 |
Pandion Therapeutics, Inc. |
Immunotolérance ciblée
|
EP3641814A4
(fr)
|
2017-06-19 |
2021-06-23 |
Medicenna Therapeutics Inc. |
Utilisations et procédés pour des superagonistes et agonistes d'il-2 et des fusions de ceux-ci
|
AU2018372167B2
(en)
|
2017-11-21 |
2023-12-07 |
The Board Of Trustees Of The Leland Stanford Junior University |
Partial agonists of interleukin-2
|
US10946068B2
(en)
|
2017-12-06 |
2021-03-16 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
US10174092B1
(en)
|
2017-12-06 |
2019-01-08 |
Pandion Therapeutics, Inc. |
IL-2 muteins
|
SG11202008979QA
(en)
*
|
2018-03-28 |
2020-10-29 |
Two Tag Holdings Pty Ltd |
Methods for measuring relative oxidation levels of a protein
|
JP2022533702A
(ja)
|
2019-05-20 |
2022-07-25 |
パンディオン・オペレーションズ・インコーポレイテッド |
MAdCAM標的化免疫寛容
|
MX2022008771A
(es)
|
2020-01-14 |
2022-10-07 |
Synthekine Inc |
Metodos y composiciones de muteinas de il2 sesgadas.
|
US11981715B2
(en)
|
2020-02-21 |
2024-05-14 |
Pandion Operations, Inc. |
Tissue targeted immunotolerance with a CD39 effector
|